Gennari et al. ( 1 ) report an interaction between HER2 status and anthracycline chemosensitivity, but they do not mention tumor grade. Multivariable analysis has revealed that Scarff -Bloom -Richardson grade III tumors respond better to neoadjuvant treatment than Scarff -BloomRichardson grade I tumors ( P < .0001) ( 2 ) . A recent study suggests that an interaction between HER2 and estrogen receptor pathways may lead to higher proliferation rate and thus a higher tumor grade ( 3 ). Therefore, inclusion of tumor grade might have increased the relative predictive value of HER2 status and grade in predicting anthracycline chemosensitivity ( 2 ). Moreover, among patients who have HER2-negative, estrogen receptor -positive breast cancer, those with higher tumor grades may benefit from anthracycline ( 2 ) . Furthermore, among patients who have HER2-negative, estrogen receptor -negative, and progesterone receptor -negative breast cancer, we have demonstrated a high rate of pathological complete response ( 4 ), which is an accepted surrogate of improved survival ( 5 , 6 ) . Of the 15 patients who received four cycles of dose-dense anthracycline (doxorubicin) and cyclophosphamide followed by three cycles of paclitaxel (cremophor or albumin-bound paclitaxel) plus or minus carboplatin (both at 3 weeks on, 1 week off for one cycle) plus or minus six doses of bevacizumab every 2 weeks, 9 (60%; 95% confidence interval = 32% to 84%) achieved pathological complete response ( 4 ) . Specifically, with anthracyclines given biweekly compared with every 3 weeks, there is a higher pathological complete response and, as a result, improved survival ( 7 ) . Therefore, the pooled analysis needs to be replicated or refuted in the biweekly anthracycline setting, specifically in estrogen receptor -negative breast cancer.
Response
Dr Mehta correctly points out that there may be subgroups of HER2-negative patients who would benefit from the use of anthracycline-containing adjuvant chemotherapy, and she suggests that some anthracycline-containing regimens (especially the dose-dense ones) may be more effective than others. With regard to the first issue, individual patient data were not available for all studies in our meta-analysis, which was conducted on published data; as a consequence, the subgroup analyses she advocates are not possible. However, two points must be stressed. First, this hypothetical subgroup of anthracycline-sensitive patients, if it does indeed exist, is likely to be quite small; otherwise, to explain the lack of any effect in the overall group of HER2-negative patients observed in our analysis (hazard ratio for disease-free survival = 1.00; 95% confidence interval [CI] = 0.90 to 1.11; P = .75, hazard ratio for overall survival = 1.03; 95% CI = 0.92 to 1.16; P = .60), it would be necessary to assume that anthracyclines are detrimental in the remaining hypothetically unsensitive patients, a rather implausible hypothesis. Second, the high sensitivity to chemotherapy of high-grade breast tumors mentioned by Dr Mehta, per se, does not indicate that these tumors are more sensitive to anthracycline-containing regimens than to other regimens: to our knowledge, there are no reports linking higher grade to increased sensitivity to anthracyclines. As far as dose intensity is concerned, three studies ( 1 -3 ) have indicated that dose-dense anthracycline-based regimes are more effective than standard density regimens in HER2-positive patients but not in HER2-negative patients, indirectly supporting our conclusions and confirming that the differential sensitivity to anthracyclines, according to HER2 status, may have a molecular basis. Finally, we agree with Dr Mehta that choosing the appropriate adjuvant therapy for triple negative (ie, HER2-, estrogen receptor -, and progesterone receptor -negative) patients is challenging and that new studies or meta-analyses of previous studies that are based on individual patient and tumor data are needed to answer this question.
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